Immunitybio (IBRX) Stock Performance
Trading activity
The last 24‑hour trading period, ending at 02:59 PM Central Europe on Wednesday, 21 October 2026, saw Immunitybio shares rise by 4.16 %.
The current trading price on major exchanges is USD 8.77.
Approximately USD 123.5 million of Immunitybio shares were traded in the same period.
Market metrics
Shares outstanding: 1.1 billion.
Market capitalization: USD 8.9 billion.
24‑hour trading volume: USD 123.5 million.
30‑day price change since the previous month‑end: +3.79 %.
200‑day simple moving average: USD 7.66.
52‑week high: USD 12.43 (recorded on 25 February 2026).
52‑week low: USD 1.95 (recorded on 31 December 2025).
Comparative Performance of Related Stocks (Last 24 Hours)
| Symbol | Company | 24‑hr % change | Current price | Market cap | P/E (where available) | Additional Notes |
|---|---|---|---|---|---|---|
| RRX | Regal Rexnord | –0.95 % | USD 156.03 | USD 10.5 bn | 32.42 | – |
| QXO | QXO, Inc. | +3.16 % | USD 10.46 | USD 10.5 bn | – | 21 Oct 2026: Schedule 13G amendment, 4.5 % stake by reporting person; Form 4 transaction by president and COO (218,531 shares acquired; no sale). |
| HII | Huntington Ingalls Industrie | +0.96 % | USD 272.23 | USD 10.6 bn | 16.14 | – |
| ALGN | Align Technology | +1.01 % | USD 150.50 | USD 10.6 bn | 25.83 | Shares purchased three years ago fell from ~USD 270 to ~USD 150, a 45 % decline. |
| BMRN | Biomarin Pharmaceutical | +3.24 % | USD 56.44 | USD 10.6 bn | 144.38 | – |
Company Overview – Immunitybio, Inc.
- Sector: Health Care (Biotechnology)
- Headquarters: Culver City, United States
- Business focus: Development of cell and immunotherapy products for cancers, infectious diseases, and inflammatory conditions.
- Strategic objective: To advance therapeutic options through innovative cell‑based and immunotherapy technologies.
